Bennicas & Associates’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | $1.84M | Sell |
25,506
-350
| -1% | -$26.4K | 1.06% | 30 |
|
|
2022
Q3 | $1.84M | Sell |
25,856
-150
| -0.6% | -$10.9K | 1.17% | 28 |
|
|
2022
Q2 | $2M | Hold |
26,006
| – | – | 1.17% | 27 |
|
|
2022
Q1 | $1.9M | Sell |
26,006
-62
| -0.2% | -$4.16K | 0.95% | 36 |
|
|
2021
Q4 | $1.63M | Sell |
26,068
-1
| -0% | -$59 | 0.85% | 41 |
|
|
2021
Q3 | $1.54M | Hold |
26,069
| – | – | 0.87% | 42 |
|
|
2021
Q2 | $1.74M | Sell |
26,069
-100
| -0.4% | -$6.52K | 0.96% | 39 |
|
|
2021
Q1 | $1.65M | Sell |
26,169
-274
| -1% | -$17K | 0.95% | 40 |
|
|
2020
Q4 | $1.64M | Sell |
26,443
-150
| -0.6% | -$9.22K | 0.96% | 34 |
|
|
2020
Q3 | $1.6M | Sell |
26,593
-168
| -0.6% | -$10.1K | 1% | 33 |
|
|
2020
Q2 | $1.57M | Sell |
26,761
-14
| -0.1% | -$837 | 1.18% | 27 |
|
|
2020
Q1 | $1.49M | Sell |
26,775
-1,900
| -7% | -$116K | 1.32% | 24 |
|
|
2019
Q4 | $1.84M | Sell |
28,675
-300
| -1% | -$17.2K | 1.33% | 26 |
|
|
2019
Q3 | $1.47M | Hold |
28,975
| – | – | 1.14% | 33 |
|
|
2019
Q2 | $1.31M | Sell |
28,975
-200
| -0.7% | -$9.32K | 1.1% | 35 |
|
|
2019
Q1 | $1.39M | Hold |
29,175
| – | – | 1.22% | 32 |
|
|
2018
Q4 | $1.52M | Sell |
29,175
-200
| -0.7% | -$10.7K | 1.4% | 23 |
|
|
2018
Q3 | $1.82M | Hold |
29,375
| – | – | 1.58% | 14 |
|
|
2018
Q2 | $1.63M | Sell |
29,375
-200
| -0.7% | -$10.8K | 1.44% | 23 |
|
|
2018
Q1 | $1.87M | Sell |
29,575
-1,150
| -4% | -$74K | 1.67% | 12 |
|
|
2017
Q4 | $1.88M | Sell |
30,725
-2,000
| -6% | -$125K | 1.64% | 16 |
|
|
2017
Q3 | $2.09M | Sell |
32,725
-600
| -2% | -$35K | 1.78% | 12 |
|
|
2017
Q2 | $1.86M | Sell |
33,325
-150
| -0.4% | -$8.16K | 1.66% | 13 |
|
|
2017
Q1 | $1.82M | Sell |
33,475
-800
| -2% | -$43.9K | 1.62% | 15 |
|
|
2016
Q4 | $2M | Sell |
34,275
-350
| -1% | -$19.1K | 1.81% | 13 |
|
|
2016
Q3 | $1.87M | Sell |
34,625
-400
| -1% | -$25.7K | 1.7% | 17 |
|
|
2016
Q2 | $2.58M | Sell |
35,025
-900
| -3% | -$63.6K | 2.31% | 10 |
|
|
2016
Q1 | $2.29M | Sell |
35,925
-1,800
| -5% | -$114K | 2.18% | 11 |
|
|
2015
Q4 | $2.6M | Sell |
37,725
-1,000
| -3% | -$66.1K | 2.51% | 6 |
|
|
2015
Q3 | $2.29M | Sell |
38,725
-6,367
| -14% | -$404K | 2.14% | 10 |
|
|
2015
Q2 | $3M | Sell |
45,092
-1,525
| -3% | -$101K | 2.46% | 6 |
|
|
2015
Q1 | $3.01M | Sell |
46,617
-5,167
| -10% | -$323K | 2.52% | 6 |
|
|
2014
Q4 | $3.06M | Sell |
51,784
-633
| -1% | -$35.7K | 2.44% | 7 |
|
|
2014
Q3 | $2.68M | Sell |
52,417
-450
| -0.9% | -$22.5K | 2.21% | 9 |
|
|
2014
Q2 | $2.56M | Sell |
52,867
-850
| -2% | -$41.9K | 2% | 11 |
|
|
2014
Q1 | $2.79M | Sell |
53,717
-3,050
| -5% | -$162K | 2.23% | 8 |
|
|
2013
Q4 | $3.02M | Sell |
56,767
-5,325
| -9% | -$271K | 2.3% | 7 |
|
|
2013
Q3 | $2.87M | Sell |
62,092
-2,500
| -4% | -$110K | 2.07% | 12 |
|
|
2013
Q2 | $2.89M | Buy |
+64,592
| New | +$2.8M | 1.99% | 11 |
|
Other funds holding BMY
AWA
Bennicas & Associates's BMY Position: Q4 2022 in Review
Bennicas & Associates reduced its Bristol-Myers Squibb (BMY) stake by 1.4% in Q4 2022, selling an estimated $26.4K and leaving 25,506 shares worth $1.84M. The position accounts for 1.06% of the portfolio, ranked #30.
Bennicas & Associates first reported a position in BMY in Q2 2013 and has held it in 39 quarters since. The position peaked at $3.06M in Q4 2014. 2,600 funds tracked by Wall St. Rank hold BMY as of Q4 2022.
- Bennicas & Associates held 25,506 shares of Bristol-Myers Squibb worth $1.84M as of Q4 2022.
- Bennicas & Associates sold 350 Bristol-Myers Squibb shares in Q4 2022, an estimated $26.4K.
- Bristol-Myers Squibb made up 1.06% of Bennicas & Associates's portfolio in Q4 2022, its #30 holding.
- Bennicas & Associates first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 39 quarters since.
- Bennicas & Associates's Bristol-Myers Squibb position peaked at $3.06M in Q4 2014.
- 2,600 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2022.
Based on Bennicas & Associates's 13F filing for Q4 2022, filed 12 Jan 2023.